A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

NCT04154072 on ClinicalTrials.gov · last registry update 2024-09-19

An unusually large phase 2: 255 participants, more than double the 110 typical for the stage. The sponsor logged completion for 14 February 2023. Primary outcome, as filed: Change in Unified Parkinson's Disease Rating Scale in combined score of Parts II and III from baseline to 36 weeks. exenatide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Neuraly, Inc.
Sponsor type: Industry
Enrollment: 255
Started: 2020-02-27
Primary completion: 2023-02-14 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Unified Parkinson's Disease Rating Scale in combined score of Parts II and III from baseline to 36 weeks

Conditions studied

Parkinson Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.